These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 9139722

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Substrate behavior of plasminogen activator inhibitor-1 is not associated with a lack of insertion of the reactive site loop.
    Gils A, Knockaert I, Declerck PJ.
    Biochemistry; 1996 Jun 11; 35(23):7474-81. PubMed ID: 8652525
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Characterization of plasminogen activator inhibitor 1 mutants containing the P13 to P10 region of ovalbumin or antithrombin III: evidence that the P13 residue contributes significantly to the active to substrate transition.
    Gils A, Vleugels N, Tobback K, Knockaert I, Declerck PJ.
    Biochim Biophys Acta; 1998 Sep 08; 1387(1-2):291-7. PubMed ID: 9748634
    [Abstract] [Full Text] [Related]

  • 6. Neutralization of plasminogen activator inhibitor-1 inhibitory properties: identification of two different mechanisms.
    Debrock S, Declerck PJ.
    Biochim Biophys Acta; 1997 Feb 08; 1337(2):257-66. PubMed ID: 9048903
    [Abstract] [Full Text] [Related]

  • 7. Type-1 plasminogen-activator inhibitor -- conformational differences between latent, active, reactive-centre-cleaved and plasminogen-activator-complexed forms, as probed by proteolytic susceptibility.
    Egelund R, Schousboe SL, Sottrup-Jensen L, Rodenburg KW, Andreasen PA.
    Eur J Biochem; 1997 Sep 15; 248(3):775-85. PubMed ID: 9342229
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Conformational changes of the reactive-centre loop and beta-strand 5A accompany temperature-dependent inhibitor-substrate transition of plasminogen-activator inhibitor 1.
    Kjøller L, Martensen PM, Sottrup-Jensen L, Justesen J, Rodenburg KW, Andreasen PA.
    Eur J Biochem; 1996 Oct 01; 241(1):38-46. PubMed ID: 8898886
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Identification of a conformationally distinct form of plasminogen activator inhibitor-1, acting as a noninhibitory substrate for tissue-type plasminogen activator.
    Declerck PJ, De Mol M, Vaughan DE, Collen D.
    J Biol Chem; 1992 Jun 15; 267(17):11693-6. PubMed ID: 1601844
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Engineering plasminogen activator inhibitor 1 mutants with increased functional stability.
    Lawrence DA, Olson ST, Palaniappan S, Ginsburg D.
    Biochemistry; 1994 Mar 29; 33(12):3643-8. PubMed ID: 8142362
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Immobilization of the distal hinge in the labile serpin plasminogen activator inhibitor 1: identification of a transition state with distinct conformational and functional properties.
    De Taeye B, Compernolle G, Dewilde M, Biesemans W, Declerck PJ.
    J Biol Chem; 2003 Jun 27; 278(26):23899-905. PubMed ID: 12686544
    [Abstract] [Full Text] [Related]

  • 16. A concerted structural transition in the plasminogen activator inhibitor-1 mechanism of inhibition.
    Blouse GE, Perron MJ, Thompson JH, Day DE, Link CA, Shore JD.
    Biochemistry; 2002 Oct 08; 41(40):11997-2009. PubMed ID: 12356300
    [Abstract] [Full Text] [Related]

  • 17. Different structural requirements for plasminogen activator inhibitor 1 (PAI-1) during latency transition and proteinase inhibition as evidenced by phage-displayed hypermutated PAI-1 libraries.
    Stoop AA, Eldering E, Dafforn TR, Read RJ, Pannekoek H.
    J Mol Biol; 2001 Jan 26; 305(4):773-83. PubMed ID: 11162091
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A novel form of the plasminogen activator inhibitor created by cysteine mutations extends its half-life: relevance to cancer and angiogenesis.
    Chorostowska-Wynimko J, Swiercz R, Skrzypczak-Jankun E, Wojtowicz A, Selman SH, Jankun J.
    Mol Cancer Ther; 2003 Jan 26; 2(1):19-28. PubMed ID: 12533669
    [Abstract] [Full Text] [Related]

  • 20. A serpin-induced extensive proteolytic susceptibility of urokinase-type plasminogen activator implicates distortion of the proteinase substrate-binding pocket and oxyanion hole in the serpin inhibitory mechanism.
    Egelund R, Petersen TE, Andreasen PA.
    Eur J Biochem; 2001 Feb 26; 268(3):673-85. PubMed ID: 11168406
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.